Philadelphia, PA – According to filings with the U.S. Securities and Exchange Commission, Innervace is raising $40,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Nader Halim played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Innervace
Innervace is a regenerative therapy company developing technology that acts as pre-formed, anatomically-inspired, implantable tissue pathways to directly replace lost connections due to brain degeneration or injury. Our lead program mimics the lost migrostriatal pathway in patients with Parkinsons disease (PD). Innervaces innovative technology has the potential to be a disease modifying technology by directly replacing neuroanatomy lost to the progression of disease. This strategy is in stark contrast to currently approved therapies that only temporarily manage symptoms. The company is based upon technology developed at the University of Pennsylvania.

To learn more about Innervace, visit http://www.innervace.com/

Contact:
Nader Halim, Chief Executive Officer
202-352-7637
nader.halim@innervace.com
https://www.linkedin.com/in/nader-halim-a47a3918/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved